Elevated IDO expression by tumor and antigen-presenting cells catalyzes the degradation of tryptophan into kynurenine, a metabolite that not only suppresses effector T cell function but also activates the AhR pathway, reinforcing the expansion and suppressive function of regulatory T cells (108). The gene discussed is IDO1; the disease is neoplasm.